摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-(3-C-methyl-β-D-ribofuranosyl)guanine | 115303-89-4

中文名称
——
中文别名
——
英文名称
9-(3-C-methyl-β-D-ribofuranosyl)guanine
英文别名
2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-4-methyloxolan-2-yl]-1H-purin-6-one
9-(3-C-methyl-β-D-ribofuranosyl)guanine化学式
CAS
115303-89-4
化学式
C11H15N5O5
mdl
——
分子量
297.271
InChiKey
FPMUSCJNVLIUAN-RUQSRZACSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.7
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    155
  • 氢给体数:
    5
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    9-(3-C-methyl-β-D-ribofuranosyl)guanine吡啶三甲基氯硅烷diphenyl phosphite 作用下, 反应 6.0h, 生成 (2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-2-(2-isobutyramido-6-oxo-1H-purin-9(6H)-yl)-4-methoxytetrahydrofuran-3-yl hydrogen phosphonate
    参考文献:
    名称:
    NOVEL STING AGONISTS
    摘要:
    本发明提供了式I′的化合物: 其中 , W, X, Y, Z, Z 1 , Z 2 , R 1 , R 2 , R 3 , R 4 和R 5 如本文所定义,或其立体异构体、互变异构体、药学上可接受的盐、前药酯或溶剂化合物形式,其中所有变量均如本文所定义。这些化合物能有效调节STING蛋白,因此可用作治疗或预防受STING激动影响的疾病的药物。
    公开号:
    US20200131209A1
  • 作为产物:
    描述:
    3-O-acetyl-5-O-benzoyl-1,2-O-isopropylidene-3-C-methyl-α-D-ribofuranose 在 ammonium hydroxide 作用下, 反应 48.0h, 生成 9-(3-C-methyl-β-D-ribofuranosyl)guanine
    参考文献:
    名称:
    3-O-乙酰基-5-O-苯甲酰基-1,2-O-异亚丙基-3-C-甲基-α-d-呋喃核糖的乙酰分解过程中的差向异构。具有β-d-核糖-和α-d-阿拉伯糖构型的3'-C-甲基核苷的合成
    摘要:
    摘要用高浓度乙酸将3-O-乙酰基-5-O-苯甲酰基-1,2-O-异亚丙基-3-C-甲基-α-d-核呋喃糖进行乙酰化反应可得到1,2,3-tri- O-乙酰基-5-O-苯甲酰基-3-C-甲基-d-呋喃糖,用于制备3-C-甲基-α-d-呋喃糖基核苷。还从1,2,3-三-O-乙酰基-5-O-苯甲酰基-3-C-甲基-d-核呋喃糖开始合成3'-C-甲基核糖核苷。
    DOI:
    10.1016/0008-6215(88)84024-2
点击查看最新优质反应信息

文献信息

  • Purine and Pyrimidine Nucleoside Analogs of 3'-C-Methyladenosine as Antitumor Agents
    作者:Loredana Cappellacci、Palmarisa Franchetti、Riccardo Petrelli、Sara Riccioni、Patrizia Vita、Hiremagalur N. Jayaram、Mario Grifantini
    DOI:10.1135/cccc20061088
    日期:——

    3'-C-Methyladenosine (3'-Me-Ado) is a mechanism-based ribonucleotide reductase inhibitor endowed with antitumor activity against both human leukemia and carcinoma cell lines. In this paper, we report the synthesis and antitumor evaluation of a series of purine and pyrimidine 3'-C-methylribonucleoside analogs of 3'-Me-Ado. A stereoselective synthesis of the arabino analog of 3'-Me-Ado is also described. Among the tested compounds, only 3'-C-methyluridine showed moderate antitumor activity against human myelogenous leukemia K562 cell line.

    3'-C-甲基腺苷(3'-Me-Ado)是一种以机制为基础的核糖核苷酸还原酶抑制剂,具有抗肿瘤活性,可对人类白血病和癌细胞系产生作用。本文报告了一系列嘌呤和嘧啶3'-C-甲基核糖核苷类似物的合成和抗肿瘤评价,还描述了3'-Me-Ado的阿拉伯糖类似物的立体选择性合成。在测试的化合物中,只有3'-C-甲基尿苷对人类骨髓性白血病K562细胞系显示出中等的抗肿瘤活性。
  • Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections
    申请人:SOMMADOSSI Jean-Pierre
    公开号:US20090238790A2
    公开(公告)日:2009-09-24
    Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    本文提供了用于治疗肝脏疾病,包括HCV和/或HBV感染的化合物、组合物和方法。具体来说,披露了核苷衍生物的化合物和组合物,可以单独或与其他抗病毒药物联合使用。
  • Compounds and pharmaceutical compositions for the treatment of viral infections
    申请人:Sommadossi Jean-Pierre
    公开号:US20080286230A1
    公开(公告)日:2008-11-20
    Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    本文提供了用于治疗肝脏疾病,包括HCV和/或HBV感染的化合物、组合物和方法。具体地,本文公开了核苷衍生物的化合物和组合物,可以单独或与其他抗病毒药物联合使用。
  • COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
    申请人:SOMMADOSSI Jean-Pierre
    公开号:US20110286962A1
    公开(公告)日:2011-11-24
    Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    本文提供了治疗肝脏疾病,包括HCV和/或HBV感染的化合物、组合物和方法。具体地,揭示了核苷衍生物的化合物和组合物,可以单独或与其他抗病毒药物联合使用。
  • Compounds and Pharmaceutical compositions for the treatment of Viral infections
    申请人:Sommadossi Jean-Pierre
    公开号:US20090169504A1
    公开(公告)日:2009-07-02
    Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    本文提供了用于治疗肝脏疾病,包括HCV和/或HBV感染的化合物,组合物和方法。具体地,公开了核苷衍生物的化合物和组合物,可以单独或与其他抗病毒药物联合使用。
查看更多